Paper
0
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Authors
Timothy Perren,Ann Swart
Sokbom Kang,Jonathan Ledermann,Éric Pujade-Lauraine,Gunnar Kristensen,Mark Sculpher,Philip Beale,Andrés Cervantes,Christian Kurzeder,Andreas Bois,Jalid Sehouli,Rainer Kimmig,A. Stähle,Fiona Collinson,Sharadah Essapen,Charlie Gourley,Alain Lortholary,Frédèric Selle,Luís Manso,Dong Liang,Marie Plante,Dan Stark,Wendi Qian,Mahesh Parmar,Amit Oza,Jacobus Pfisterer,Mark Carey,Anne Stähle,Mansoor Mirza,Arto Leminen
+29 authors
,Andrès CervantesPublished
Dec 28, 2011
Show more
Save
Tip0
TipSave
Abstract
Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.